

Clinical Research Study for Children with Hereditary Angioedema (HAE)

This study is evaluating an injectable investigational drug for children who have been diagnosed with hereditary angioedema (HAE) and have HAE attacks.

The purpose of this study is to learn more about the investigational drug's safety and effectiveness in preventing HAE attacks in children. This study is an open-label study, which means all children who qualify will receive the investigational drug.

While the investigational drug has been evaluated in research studies for adults and adolescents, it is not approved to treat children with HAE. The investigational drug is only available to children with HAE in research studies like this one.

Depending on their age, eligible study patients will receive an injection of the investigational drug every month or once every two months during the 12-month treatment period. Parents/caregivers of study patients may have the option to be trained to administer their child's injections at home.

Study patients will also have study center visits for tests and evaluations every 2-3 months, including a follow-up visit about 3 months after their last injection.

Total participation in this study will last approximately 14-15 months, which includes screening for eligibility, study treatment, and follow-up.

To pre-qualify for this study, patients must:

- **Be 2 to 11 years of age**
- **Have been diagnosed with HAE (Type 1 or 2)**
- **Have had at least 2 HAE attacks during the 6 months prior to this study**

Additional criteria will apply. All study-related visits, tests, and investigational drug will be provided at no cost. In addition, reimbursement for study-related costs may be provided.

If you would like to learn more about this study or ask questions, please contact:

Alvin Mendoza (OARC, Study Coordinator)
Phone (613)725-2102 ext. 261
Email: amendoza@yangmedicine.com

Thank you for your time, and I appreciate any consideration and support you might give to this important research study.

CSL Behring
Biotherapies for Life™


Vanguard

Prove CSL312 Efficacy and Safety
to Guard Against HAE Attacks